Exponent vs ICF International
EXPO and ICFI side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EXPO and ICFI compare
Exponent is the larger company, worth 3.0 times as much as ICF International ($4.2B against $1.4B).
On earnings, ICF International is cheaper: it trades at 16.1× trailing earnings, against 39.3× for Exponent.
Exponent grew revenue faster over the last twelve months (12.8% versus −7.9% for ICF International).
Exponent keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with 4.9% at ICF International.
Both pay dividends: Exponent yields 1.4% and ICF International 0.72%.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EXPO | ICFI |
|---|---|---|
| Size and price | ||
| Market cap | $4.2B | $1.4B |
| Share price | $87.69 | $78.00 |
| Change, 1 year | 25.4% | −0.06% |
| Change, 5 years | −24.9% | −22.2% |
| Beta (5Y) | 0.24 | 1.44 |
| Employees | 1,313 | 8,400 |
| StockData Score | ||
| Total score | 20 | 20 |
| Valuation score | 2 | 6 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 5 (better) | 4 |
| Health score | 6 (better) | 4 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 39.3× | 16.1× (better) |
| P/S | 6.6× | 0.8× (better) |
| P/B | 14.4× | 1.3× (better) |
| EV/EBITDA | 29.8× | 9.1× (better) |
| P/FCF | 38.4× | 7.0× (better) |
| PEG | 21.41 | 1.19 (better) |
| FCF yield | 2.6% | 14.2% (better) |
| Fair value | $66.46 | $118.69 |
| Margin of safety | −31.9% | 34.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.8% (better) | −7.9% |
| Revenue growth, 5Y average | 7.8% (better) | 4.4% |
| Net income growth (TTM) | 8.7% (better) | −17.8% |
| EPS growth (TTM) | 11.5% (better) | −16.0% |
| EPS growth, 5Y average | 6.0% | 11.5% (better) |
| Profitability | ||
| Gross margin | – | 37.2% |
| Operating margin | 20.2% (better) | 7.8% |
| Net margin | 17.7% (better) | 4.9% |
| FCF margin | 17.2% (better) | 10.9% |
| Return on equity | 31.2% (better) | 8.6% |
| Return on invested capital | 43.8% (better) | 7.7% |
| Financial health | ||
| Debt / equity | 0.00 | 0.39 (better) |
| Net debt / EBITDA | – | 2.05 |
| Interest coverage | – | 4.9× |
| Current ratio | 1.98 (better) | 1.39 |
| Altman Z-score | 10.26 (better) | 2.65 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.4% (better) | 0.72% |
| Payout ratio | 54.8% | 11.6% |
| Years of dividend growth | 13 (better) | 0 |
| Dividend growth, 5Y average | 9.6% (better) | 0.00% |
| Buyback yield | 5.1% (better) | 3.3% |
| Shareholder yield | 6.5% (better) | 4.0% |
| Ownership | ||
| Held by institutions | 97.8% | 102% |
| Held by insiders | 1.3% | 1.8% |
| Insider net buying, 12 months | −$2.7M | −$1.4M (better) |
| Short interest, % of float | 5.2% | 3.6% |
Go deeper
- EXPO stock overview
- EXPO income statement
- EXPO valuation and score
- ICFI stock overview
- ICFI income statement
- ICFI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.